William Haning to Male
This is a "connection" page, showing publications William Haning has written about Male.
Connection Strength
0.171
-
Nakama H, Chang L, Cloak C, Jiang C, Alicata D, Haning W. Association between psychiatric symptoms and craving in methamphetamine users. Am J Addict. 2008 Sep-Oct; 17(5):441-6.
Score: 0.023
-
Haning W, Goebert D. Electrocardiographic abnormalities in methamphetamine abusers. Addiction. 2007 Apr; 102 Suppl 1:70-5.
Score: 0.020
-
Baker FM, Haning WF. Substance abuse and dependence in a public hospital: Hawaii. Hawaii Med J. 2001 Feb; 60(2):35-8.
Score: 0.013
-
Anderson AL, Li SH, Markova D, Holmes TH, Chiang N, Kahn R, Campbell J, Dickerson DL, Galloway GP, Haning W, Roache JD, Stock C, Elkashef AM. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2015 May 01; 150:170-4.
Score: 0.009
-
Kiblawi ZN, Smith LM, Diaz SD, LaGasse LL, Derauf C, Newman E, Shah R, Arria A, Huestis M, Haning W, Strauss A, DellaGrotta S, Dansereau LM, Neal C, Lester B. Prenatal methamphetamine exposure and neonatal and infant neurobehavioral outcome: results from the IDEAL study. Subst Abus. 2014; 35(1):68-73.
Score: 0.008
-
Adams D, Ditzler T, Haning WF. Primary caffeine dependence: a case report. Hawaii Med J. 1993 Jul; 52(7):190-1, 194.
Score: 0.008
-
Kirlic N, Newman E, Lagasse LL, Derauf C, Shah R, Smith LM, Arria AM, Huestis MA, Haning W, Strauss A, Dellagrotta S, Dansereau LM, Abar B, Neal CR, Lester BM. Cortisol reactivity in two-year-old children prenatally exposed to methamphetamine. J Stud Alcohol Drugs. 2013 May; 74(3):447-51.
Score: 0.008
-
Ma JZ, Johnson BA, Yu E, Weiss D, McSherry F, Saadvandi J, Iturriaga E, Ait-Daoud N, Rawson RA, Hrymoc M, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Weis D, McCann M, Pham T, Stock C, Dickinson R, Elkashef A, Li MD. Fine-grain analysis of the treatment effect of topiramate on methamphetamine addiction with latent variable analysis. Drug Alcohol Depend. 2013 Jun 01; 130(1-3):45-51.
Score: 0.008
-
Smith LM, Paz MS, LaGasse LL, Derauf C, Newman E, Shah R, Arria A, Huestis MA, Haning W, Strauss A, Della Grotta S, Dansereau LM, Neal C, Lester BM. Maternal depression and prenatal exposure to methamphetamine: neurodevelopmental findings from the infant development, environment, and lifestyle (ideal) study. Depress Anxiety. 2012 Jun; 29(6):515-22.
Score: 0.007
-
Elkashef A, Kahn R, Yu E, Iturriaga E, Li SH, Anderson A, Chiang N, Ait-Daoud N, Weiss D, McSherry F, Serpi T, Rawson R, Hrymoc M, Weis D, McCann M, Pham T, Stock C, Dickinson R, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Li MD, Johnson BA. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012 Jul; 107(7):1297-306.
Score: 0.007
-
Anderson AL, Li SH, Biswas K, McSherry F, Holmes T, Iturriaga E, Kahn R, Chiang N, Beresford T, Campbell J, Haning W, Mawhinney J, McCann M, Rawson R, Stock C, Weis D, Yu E, Elkashef AM. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2012 Jan 01; 120(1-3):135-41.
Score: 0.007
-
Zabaneh R, Smith LM, LaGasse LL, Derauf C, Newman E, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Dansereau LM, Lin H, Neal C, Lester BM. The effects of prenatal methamphetamine exposure on childhood growth patterns from birth to 3 years of age. Am J Perinatol. 2012 Mar; 29(3):203-10.
Score: 0.007
-
Derauf C, LaGasse L, Smith L, Newman E, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Dansereau L, Lin H, Lester B. Infant temperament and high-risk environment relate to behavior problems and language in toddlers. J Dev Behav Pediatr. 2011 Feb-Mar; 32(2):125-35.
Score: 0.007
-
Smith LM, LaGasse LL, Derauf C, Newman E, Shah R, Haning W, Arria A, Huestis M, Strauss A, Della Grotta S, Dansereau LM, Lin H, Lester BM. Motor and cognitive outcomes through three years of age in children exposed to prenatal methamphetamine. Neurotoxicol Teratol. 2011 Jan-Feb; 33(1):176-84.
Score: 0.007
-
Nguyen D, Smith LM, Lagasse LL, Derauf C, Grant P, Shah R, Arria A, Huestis MA, Haning W, Strauss A, Della Grotta S, Liu J, Lester BM. Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J Pediatr. 2010 Aug; 157(2):337-9.
Score: 0.006
-
Gray TR, LaGasse LL, Smith LM, Derauf C, Grant P, Shah R, Arria AM, Della Grotta SA, Strauss A, Haning WF, Lester BM, Huestis MA. Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the Infant Development, Environment and Lifestyle (IDEAL) study. Ther Drug Monit. 2009 Dec; 31(6):769-75.
Score: 0.006
-
Smith LM, Lagasse LL, Derauf C, Grant P, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Fallone M, Liu J, Lester BM. Prenatal methamphetamine use and neonatal neurobehavioral outcome. Neurotoxicol Teratol. 2008 Jan-Feb; 30(1):20-8.
Score: 0.005
-
Elkashef AM, Rawson RA, Anderson AL, Li SH, Holmes T, Smith EV, Chiang N, Kahn R, Vocci F, Ling W, Pearce VJ, McCann M, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Weis D. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology. 2008 Apr; 33(5):1162-70.
Score: 0.005
-
Elkashef A, Rawson RA, Smith E, Pearce V, Flammino F, Campbell J, Donovick R, Gorodetzky C, Haning W, Mawhinney J, McCann M, Weis D, Williams L, Ling W, Vocci F. The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity. Addiction. 2007 Apr; 102 Suppl 1:107-13.
Score: 0.005
-
Smith LM, LaGasse LL, Derauf C, Grant P, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Liu J, Lester BM. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics. 2006 Sep; 118(3):1149-56.
Score: 0.005